Loading companies…
United States · Biotech
An AI and synthetic-biology platform that designs and engineers antibody therapeutics.
BigHat combines machine learning with synthetic biology to design and optimize antibody candidates across multiple properties. Its platform also generates experimental data for rapid protein design, linking computational models with laboratory work. The Series C is intended to advance the company’s clinical-stage therapeutics pipeline and expand its data platform for antibody engineering.
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series C | $75M | DFJ Growth — LeadPremji Invest — Lead8VC — ParticipantAmgen — ParticipantAndreessen Horowitz — ParticipantCatalio Capital Management — ParticipantDiscovery Ventures — ParticipantGRIDS Capital — ParticipantIntermountain Ventures — ParticipantQuadrille Capital — Participant |